All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

NCCN Adds Olutasidenib to Guidelines for Relapsed/Refractory, IDH1-Mutant AML

January 18th 2023

Olutasidenib has been added to the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology as a recommended targeted therapy for adult patients with relapsed/refractory acute myeloid leukemia with an IDH1 mutation.

Perioperative Toripalimab Plus Chemotherapy Meets EFS End Point in NSCLC

January 18th 2023

Perioperative treatment with the combination of toripalimab plus platinum-containing doublet chemotherapy, followed by toripalimab monotherapy as consolidation therapy after surgery, significantly extended event-free survival compared with chemotherapy plus placebo in patients with operable NSCLC.

Developing Culturally Concordant Palliative Care for Hindu Patients and Families

January 18th 2023

Sometimes, clinicians do not acknowledge how patients' values and beliefs influence how they ascribe meaning to their illness, how they prefer to receive information, and how they make decisions until the end-of-life stage, leading to misunderstandings between clinicians and patients.

Updates From 2022 SABCS Underscore the Continued Expansion of Treatment Options in Metastatic Breast Cancer

January 18th 2023

Virginia F. Borges, MD, MMSc, and colleagues highlight updates across the breast cancer landscape, including key updates from the 2022 SABCS.

MRI-Guided Radiotherapy Significantly Reduces Genitourinary, Gastrointestinal AEs in Prostate Cancer

January 17th 2023

Patients who received MRI-guided stereotactic body radiotherapy for prostate cancer experienced fewer moderate acute physician-scored genitourinary and gastrointestinal adverse effects compared with those who received computed tomography–guided stereotactic body radiotherapy.

Neoadjuvant Anti-HER2 TKIs Require Further Investigation for HER2+ Breast Cancer

January 17th 2023

John Crown, MB, BCh, BAO, BSc, MD, MBA, discusses previous research with anti-HER2 TKIs in HER2-positive breast cancer, expanded on key follow-up data from this phase 2 trial, and emphasized the importance of continued investigation into this underutilized combination.

TP-3654 Showcases Early Signs of Tolerability, Clinical Activity in Myelofibrosis

January 17th 2023

The PIM1 kinase inhibitor TP-3654 was well tolerated and showcased preliminary signs of activity, including spleen volume reduction, symptom improvement, and broad cytokine reduction, in patients with myelofibrosis who were previously treated with or were ineligible for a JAK inhibitor.

Orca-Q Demonstrates Encouraging GRFS, Tolerability, and Low GVHD Incidence in Hematologic Cancers

January 17th 2023

Amandeep Salhotra, MD, provides insight on the data with Orca-Q shared during the 2022 ASH Annual Meeting.

ACCC Releases New Oncology Practice Transformation and Integration Center (OPTIC) Resource Library

January 17th 2023

The Association of Community Cancer Centers is announcing the release of a new tool intended to facilitate education and adoption of new clinical and technological advancements in diagnosis, staging, and treatment of cancer.

Genetic Analysis Helps Maximize Clinical Benefit with PARP Inhibitors in BRCA+ Ovarian Cancer

January 17th 2023

Saketh Guntupalli, MD, highlights data supporting PARP inhibitors as the standard-of-care frontline therapy, strategies for the management of PARP-related toxicities, and the importance of testing for HRD and BRCA status in patients with ovarian cancer.

Considerations When Treating Patients With Metastatic Renal Cell Carcinoma

January 17th 2023

Similar to first-line therapy choices, particular treatment factors, including type and duration of response to prior therapy, pace of disease progression, and toxicities associated with first-line treatment, are all practical considerations that help guide therapy selection in metastatic renal cell carcinoma.

Tusamitamab Ravtansine Is Under Investigation in CEACAM5+ Nonsquamous NSCLC

January 17th 2023

Tusamitamab ravtansine, an antibody-drug conjugate that targets CEACAM5, could expand the treatment armamentarium for patients with CEACAM5-positive nonsquamous non–small cell lung cancer.

Daratumumab, Lenalidomide, Dexamethasone Improves OS in Relapsed/Refractory Multiple Myeloma

January 16th 2023

The addition of daratumumab to lenalidomide and dexamethasone led to a 27% reduction in the risk of death compared with Rd alone in patients with relapsed/refractory multiple myeloma.

Neoadjuvant Immunotherapy Elicits Strong Responses in Localized dMMR/MSI-H Colorectal Cancer

January 16th 2023

Neoadjuvant treatment with anti–PD-1 inhibitors induced high rates of complete response and reduced recurrence rates, according to a retrospective analysis of patients with localized mismatch repair-deficient or microsatellite instability–high colorectal cancer.

FDA Grants Orphan Drug Designation to JBI-802 for Small Cell Lung Cancer and AML

January 16th 2023

The FDA has granted an orphan drug designation to JBI-802 for the treatment of patients with small cell lung cancer and acute myeloid leukemia.

Study Supports Urging Smoking-Cessation Treatment to Patients in Cancer Care

January 16th 2023

New research including Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis indicates it’s both possible and helpful to get cancer patients who smoke into evidence-based tobacco-treatment programs as part of their cancer care.

R-DHAP Regimen Produces Favorable Efficacy in Younger MCL Patients

January 16th 2023

R-DHAP plus high-dose cytarabine-containing myeloablative radiochemotherapy conditioning and autologous stem cell transplant demonstrated sustained time to treatment failure and overall survival benefits vs R-CHOP plus standard myeloablative radiochemotherapy and ASCT in patients with mantle cell lymphoma aged 65 years and younger.

Targeting FRα Enters a New Era in Ovarian Cancer and Beyond

January 16th 2023

Efforts to target the folate metabolism network have entered a new stage, with the approval of a novel therapy directed at folate receptor–α and the potential for additional agents aimed at that target in solid tumors.

Axi-cel Maintains PFS and ORR Benefit in 3-Year Follow-Up of ZUMA-5 in Indolent NHL

January 16th 2023

Axicabtagene ciloleucel continued to elicit improved progression-free survival and overall response rates in patients with relapsed/refractory indolent non-Hodgkin lymphoma.

Zanubrutinib Extends Treatment Duration in Acalabrutinib-Intolerant Patients With B-cell Malignancies

January 16th 2023

Patients with B-cell malignancies who were intolerant to acalabrutinib experienced a longer treatment duration when subsequently receiving zanubrutinib.